The current rally is being driven by momentum. If this continues then look for the move to extend into the main 50% level at $1970.10. …read more […]
Chief among their concerns: that small-caps will bear the brunt of aggressive measures Biden could adopt to combat the pandemic, without benefiting from a large stimulus bill if Senate Republicans block his efforts there. Democrats could still take over the Senate if Georgia’s two contested seats go to a January runoff as is now expected. …read more […]
2020 has provided a reversal of fortune for MannKind (MNKD). After several difficult years, the diabetes focused biotech’s stock has been on the mend and is up by 77% year-to-date.However, according to BTIG analyst Robert Hazlett, there’s plenty of upside yet to come. The 5-star analyst has a Buy rating on MNKD shares along with a $4 price target. Investors could be pocketing gains of a hefty 75%, should Hazlett’s thesis play out over the coming months. (To watch Hazlett’s track record, click here)Hazlett’s confidence in MannKind is based on 2 main drivers; The first is the increasing sales of …read more […]
Some companies can’t wait to put 2020 behind them but at Qualcomm (QCOM) HQ, they might be wishing it never ends.The semiconductor giant has brushed aside any Covid-19 and macro headwinds, and totally shocked the market after blowing its fiscal fourth-quarter earnings out of the water.In FQ4, Qualcomm delivered revenue of $6.5 billion, a year-over-year increase of 35.1%, beating the estimates by $560 million. The bottom-line results flew past the Street’s forecast too, with Non-GAAP EPS of $1.45 coming in $0.27 ahead of consensus.While this earnings season has been characterized by strong results only to be let down by weak …read more […]
Semiconductor stocks have been on a tear in 2020, but the same cannot be said about one of the sector’s heavyweights – Micron (MU).Hampered by a series of negative macro events and the loss of a big chunk of revenue due to the recent ban on Huawei, the company has suffered at the hands of Mr. Market and has been struggling to swing into the green in 2020.However, despite the company issuing soft estimates, the stock has mostly trended upwards since late September when Micron delivered strong FQ4 results.So, is the trend likely to continue?Based on competitor SK Hynix’ latest …read more […]
Mark Hamrick, Bankrate.com Senior Economic Analyst, joined Yahoo Finance Live to discuss his biggest takeaways from the October jobs report and what it signals for the future of the labor market. …read more […]
The 2 funds seek capital appreciation in stocks that pay dividends …read more […]
Nouriel Roubini, professor of economics at New York University’s Stern School of Business and CEO of Roubini Macro Associates, joined Yahoo Finance Live to give his take on Bitcoin and his outlook for the economy. …read more […]
There are lots of great apps out there for traders. But in this M1 Finance review, we’ll show you why this online brokerage is ideal not just for traders… but for investors as well.
Where the name M1 Finance comes from is a bit of a mystery. So, we’re not saying it comes from the M1 carbine – the standard firearm in the U.S. military for decades – but the two do share some similarities. For instance…
The M1 carbine was lightweight and practical. M1 Finance fits anywhere your smartphone does and offers the chance to easily invest from anywhere.
The M1 carbine …read more […]
Yahoo Finance’s Alexis Christoforous and Landon Luxembourg, Third Bridge senior analyst, discuss Peloton earnings. …read more […]
(Bloomberg) — Palantir Technologies Inc. surged on Friday as Democrat Joe Biden moved closer to a victory in the U.S. presidential election.The stock rose as much as 26%, the most since its direct listing in September as many investors expect defense spending would be cut under a Biden administration.Palantir, which was co-founded by Peter Thiel, counts the U.S. Defense Department among its largest customers and could benefit from reduced spending because its software often costs less than similar offerings from traditional defense contractors.Its shares could also be benefiting from short sellers exiting their positions as the stock rises, according to …read more […]
(Bloomberg) — Biogen Inc.’s experimental Alzheimer’s disease therapy failed to gain support from a panel of U.S. Food and Drug Administration advisers on Friday, putting the drug at a crossroads as the agency weighs approval.The advisers voted 8 to 1, with 2 undecided, that data from a single clinical trial with positive results was insufficient to show the drug works in light of conflicting evidence from a different trial. The vote contradicts a report FDA reviewers prepared ahead of the meeting that supported the efficacy of the drug, called aducanumab, though there was dissent in the agency.Shares of Biogen were …read more […]
Fundstrat’s Tom Lee nailed the March market bottom. Now, he says the VIX is proving that the stock market doesn’t care too much about Trump’s election challenge. …read more […]
This guest post has been written by our friend Melissa Brock over at Benzinga, where you can find reviews for many financial products that could help you secure your financial future. In the following article, Melissa explains all the steps you should be taking to learn how to build an emergency fund and why it’s so important to do so. By the time you finish reading, you’ll know exactly what to do.
In your heart of hearts, you know you need an emergency fund. But how do you build one? How do you save for it? What is it, really?
We’ll supply …read more […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
